Streetbeat News

Regulatory

CDAQ

Trading has been halted at 7:25:00 a.m. ET due to pending news. This halt affects the CDAQ, which may indicate significant news is forthcoming.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 11:25 am

NDAQ

Nasdaq reaffirms its medium-term growth outlook for all divisions, including AxiomSL and Calypso, and maintains its 2024 expectations. A $32 million one-time, non-cash GAAP revenue reduction will be recorded in Q3 2024 due to an accounting change affecting AxiomSL subscription revenue.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 11:11 am

AXGN

Axogen has completed the submission of a Biologics License Application to the FDA for its Avance Nerve Graft, a significant step in the regulatory process for the product.

Portfolio Pulse from Nabaparna Bhattacharya

September 06, 2024 | 11:10 am

NDAQ

Nasdaq has announced a change in the accounting treatment of revenues related to AxiomSL on-premises subscription contracts. This adjustment may impact how revenues are reported in future financial statements.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 11:09 am

GSK

VRNA

GSK's asthma drug Nucala met its primary goal in a Phase 3 trial for COPD, showing significant reduction in exacerbations. This positions GSK to compete with Amgen/AstraZeneca's similar drug. Nucala is not yet approved for COPD, but the trial results may influence future regulatory discussions.

Portfolio Pulse from Vandana Singh

September 06, 2024 | 10:56 am

KALV

KalVista Pharmaceuticals presented new analyses on the efficacy and safety of Sebetralstat, an investigational treatment for hereditary angioedema, at the Bradykinin Symposium 2024. The data includes results from Phase 2 and Phase 3 trials, as well as interim data from an open-label extension trial.

Portfolio Pulse from Nabaparna Bhattacharya

September 06, 2024 | 10:35 am

NPSCY

X

The U.S. is considering blocking Nippon Steel's acquisition of U.S. Steel due to national security concerns, causing tension with Japan. Japanese leaders warn this could harm U.S.-Japan relations. The deal faces opposition from U.S. labor unions and political figures.

Portfolio Pulse from Benzinga Neuro

September 06, 2024 | 9:45 am

AAL

DAL

LUV

UAL

The U.S. Transportation Department is investigating the rewards programs of major airlines, including American Airlines, Delta, Southwest, and United, to ensure fair treatment of consumers. The probe focuses on issues like devaluation of rewards and hidden fees.

Portfolio Pulse from Benzinga Neuro

September 06, 2024 | 9:44 am

GOOG

GOOGL

The UK's Competition and Markets Authority (CMA) is investigating Google for potentially abusing its dominant position in the ad tech sector. This investigation could have implications for Google's business operations and market position.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 9:13 am

BCRX

BioCryst Pharmaceuticals presented new data on hereditary angioedema (HAE) treatment at the 7th Bradykinin Symposium. The APeX-N trial interim results showed the effectiveness and safety of berotralstat, an oral prophylaxis for HAE, in Europe. The study also emphasized the importance of shared decision-making between healthcare providers and patients for optimal outcomes.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 7:02 am